Axsome Therapeutics, Inc. (AXSM) Ownership
AXSM ownership summary
as of October 17, 2026- Institutions
- 74.3% of shares outstanding
- Insiders
- 15.08% of shares outstanding
- Shares outstanding
- 52.4M
- Float
- 44.5M shares available to trade
- Short interest
- 9.79% 3.3M shares short
- Days to cover
- 4.80 short interest up 5.3% vs prior month
- Institutions 74.31%
- Insiders 15.08%
- Other investors 10.61%
AXSM top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | BlackRock Inc | 5.93% | 3.1M | $487.7M | −809,136 (−20.7%) | June 30, 2026 |
| 2 | Vanguard Portfolio Management, LLC | 3.79% | 2.0M | $311.7M | −74,656 (−3.6%) | June 30, 2026 |
| 3 | Vanguard Capital Management, LLC | 3.75% | 2.0M | $308.8M | +27,334 (+1.4%) | June 30, 2026 |
| 4 | Amvescap Plc. | 3.19% | 1.7M | $262.7M | +374,006 (+28.8%) | June 30, 2026 |
| 5 | FMR Inc | 2.94% | 1.5M | $241.9M | −27,832 (−1.8%) | June 30, 2026 |
| 6 | Geode Capital Management, LLC | 1.85% | 967K | $152.0M | −195,809 (−16.8%) | June 30, 2026 |
| 7 | Assenagon Asset Management SA | 1.74% | 909K | $142.9M | +43,406 (+5.0%) | June 30, 2026 |
| 8 | Morgan Stanley - Brokerage Accounts | 1.54% | 804K | $126.4M | +327,381 (+68.7%) | June 30, 2026 |
| 9 | State Street Corp | 1.50% | 786K | $123.5M | −201,148 (−20.4%) | June 30, 2026 |
| 10 | Deep Track Capital, LP | 1.34% | 700K | $110.0M | −400,000 (−36.4%) | June 30, 2026 |
| 11 | Two Sigma Investments LLC | 1.28% | 669K | $105.2M | +346,700 (+107.4%) | June 30, 2026 |
| 12 | Franklin Templeton Inc | 1.28% | 668K | $105.0M | +229,883 (+52.4%) | June 30, 2026 |
| 13 | Wellington Management Company LLP | 1.25% | 654K | $102.8M | −491,386 (−42.9%) | June 30, 2026 |
| 14 | Alethea Capital Management, LLC | 1.24% | 649K | $101.9M | −358 (−0.1%) | June 30, 2026 |
| 15 | T. Rowe Price Associates, Inc. | 1.23% | 643K | $101.0M | −674,166 (−51.2%) | June 30, 2026 |
| 16 | D. E. Shaw & Co LP | 1.15% | 605K | $95.0M | +1,288 (+0.2%) | June 30, 2026 |
| 17 | Millennium Management LLC | 1.06% | 556K | $87.4M | +535,330 (+2,578.9%) | June 30, 2026 |
| 18 | Delaware Management Holdings Inc | 1.03% | 539K | $84.8M | −273,402 (−33.6%) | June 30, 2026 |
| 19 | NORGES BANK | 0.98% | 514K | $80.8M | +18,810 (+3.8%) | June 30, 2026 |
| 20 | First Trust Advisors L.P. | 0.92% | 482K | $75.8M | −95,418 (−16.5%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 9 holders added 1.9M shares and 11 cut 3.2M.
AXSM top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.66% | 1.4M | $218.7M | −1,702 (−0.1%) | August 31, 2026 |
| 2 | Vanguard Small Cap Index | 1.92% | 1.0M | $158.2M | +1,456 (+0.1%) | August 31, 2026 |
| 3 | Vanguard MStar Small Cap Growth Indx Inv | 1.10% | 578K | $90.8M | −4,167 (−0.7%) | August 31, 2026 |
| 4 | Invesco Discovery A | 1.02% | 535K | $84.1M | +44,189 (+9.0%) | August 31, 2026 |
| 5 | Vanguard Explorer Inv | 0.97% | 506K | $79.5M | +140,571 (+38.5%) | June 30, 2026 |
| 6 | First Trust NYSE Arca Biotech ETF | 0.74% | 387K | $60.9M | — | September 30, 2026 |
| 7 | iShares Biotechnology ETF | 0.66% | 344K | $54.0M | −2,600 (−0.8%) | September 30, 2026 |
| 8 | Franklin DynaTech A | 0.60% | 312K | $49.0M | +12,116 (+4.0%) | August 31, 2026 |
| 9 | Fidelity Select Biotechnology | 0.54% | 284K | $44.7M | — | August 31, 2026 |
| 10 | Eventide Gilead N | 0.49% | 257K | $40.4M | −98,600 (−27.7%) | June 30, 2026 |
| 11 | Pictet-Biotech P USD | 0.47% | 246K | $38.7M | −997 (−0.4%) | June 30, 2026 |
| 12 | iShares Russell Mid-Cap Growth ETF | 0.46% | 243K | $38.2M | −261 (−0.1%) | September 30, 2026 |
| 13 | Schwab US Small-Cap ETF™ | 0.45% | 234K | $36.8M | +153 (+0.1%) | September 30, 2026 |
| 14 | Nomura Small Cap Core I | 0.44% | 229K | $35.9M | — | August 31, 2026 |
| 15 | MEDICAL BioHealth EUR Acc | 0.41% | 217K | $34.1M | +70,654 (+48.2%) | August 31, 2026 |
| 16 | Fidelity Extended Market Index | 0.40% | 210K | $33.0M | −1,952 (−0.9%) | August 31, 2026 |
| 17 | Putnam Small Cap Growth A | 0.39% | 206K | $32.4M | −6,072 (−2.9%) | August 31, 2026 |
| 18 | Hood River Small-Cap Growth Instl | 0.36% | 190K | $29.8M | — | June 30, 2026 |
| 19 | iShares Russell Mid-Cap ETF | 0.34% | 178K | $28.0M | +323 (+0.2%) | September 30, 2026 |
| 20 | Fidelity Small Cap Growth | 0.33% | 173K | $27.1M | — | July 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
AXSM insider transactions
latest 20| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-22 | Ari Maizel | Sell | $182.42 | 7,500 | $1.4M |
| 2026-02-26 | Mark Coleman | Sell | $161.11 | 25,000 | $4.0M |
| 2026-02-26 | Mark L Jacobson | Sell | $161.88 | 35,378 | $5.7M |
| 2026-02-02 | Herriot Tabuteau | Sell | $185.60 | 32,410 | $6.0M |
| 2026-01-22 | Nick Pizzie | Sell | $187.92 | 12,000 | $2.3M |
| 2026-01-21 | Ari Maizel | Sell | $184.44 | 7,500 | $1.4M |
| 2026-01-07 | Herriot Tabuteau | Sell | $170.38 | 31,261 | $5.3M |
| 2026-01-06 | Herriot Tabuteau | Sell | $172.33 | 29,450 | $5.1M |
| 2026-01-05 | Herriot Tabuteau | Sell | $171.28 | 78,703 | $13.5M |
| 2025-12-31 | Mark E Saad | Sell | $165.18 | 37,577 | $6.2M |
| 2025-12-04 | Herriot Tabuteau | Sell | $148.18 | 10,558 | $1.6M |
| 2025-12-03 | Herriot Tabuteau | Sell | $146.94 | 20,163 | $3.0M |
| 2025-12-02 | Herriot Tabuteau | Sell | $144.59 | 49,252 | $7.1M |
| 2025-11-05 | Herriot Tabuteau | Sell | $134.49 | 21,775 | $2.9M |
| 2025-11-04 | Herriot Tabuteau | Sell | $133.79 | 50,459 | $6.8M |
| 2025-11-03 | Herriot Tabuteau | Sell | $132.34 | 91,705 | $12.1M |
| 2025-10-08 | Herriot Tabuteau | Sell | $118.84 | 12,774 | $1.5M |
| 2025-10-07 | Herriot Tabuteau | Sell | $118.77 | 13,390 | $1.6M |
| 2025-10-06 | Herriot Tabuteau | Sell | $120.17 | 19,220 | $2.3M |
| 2025-09-22 | Mark L Jacobson | Sell | $115.96 | 10,000 | $1.2M |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
AXSM shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns AXSM
Institutional investors own 74.3% of Axsome Therapeutics's shares and insiders 15.08%. The largest holder is BlackRock Inc with 5.93% of the shares (3.1M), as of June 30, 2026. Among the top 20 institutions, 9 added shares and 11 reduced their stake in the latest filings. Short interest is 9.79% of the float, or 4.80 days of average trading volume. The share count rose 298.1% since 2014.
Related: AXSM analyst forecast, AXSM key metrics. See the AXSM stock overview for the latest quote and news.
AXSM ownership FAQ
Who owns the most Axsome Therapeutics stock?
The largest shareholders of Axsome Therapeutics are BlackRock Inc (5.93%), Vanguard Portfolio Management, LLC (3.79%), Vanguard Capital Management, LLC (3.75%), Amvescap Plc. (3.19%), FMR Inc (2.94%).
What percentage of Axsome Therapeutics is owned by institutions?
Institutions hold 74.3% of Axsome Therapeutics's shares outstanding; insiders hold 15.08%.
Which funds own Axsome Therapeutics?
The largest fund holders of Axsome Therapeutics are Vanguard MStar Total Stk Mkt Idx Invest (2.66%), Vanguard Small Cap Index (1.92%), Vanguard MStar Small Cap Growth Indx Inv (1.10%), Invesco Discovery A (1.02%), Vanguard Explorer Inv (0.97%).
What is Axsome Therapeutics's short interest?
3.3M shares of Axsome Therapeutics were sold short, 9.79% of the float; at the average daily volume it would take 4.80 days to cover.
Are insiders buying or selling Axsome Therapeutics?
Of the latest 20 reported insider transactions in Axsome Therapeutics (since September 22, 2025), 0 were purchases and 20 were sales.
How many shares of Axsome Therapeutics are outstanding?
Axsome Therapeutics has 52.4M shares outstanding, of which 44.5M are in the public float.